tag:blogger.com,1999:blog-4241416962008169508.post347595296791854068..comments2024-03-27T21:03:58.972-04:00Comments on Just A Life Sciences Blog...: A Recap -- FDA Approved Indications For Keytruda®: As Of August 6, 2016Unknownnoreply@blogger.comBlogger5125tag:blogger.com,1999:blog-4241416962008169508.post-53183028972764531422016-10-27T12:02:43.364-04:002016-10-27T12:02:43.364-04:00I agree that it comes down to a question of reimbu...I agree that it comes down to a question of reimbursement, as you note.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-55912373204393895702016-10-26T19:36:54.689-04:002016-10-26T19:36:54.689-04:00I do hear you -- I just think testing for all pati...I do hear you -- I just think testing for all patients is the new normal in NSCLC... for all three (including off-label -- for Tecentriq). <br /><br />So with three potential therapies... it will be a reimbursement question.<br /><br />We shall see.<br /><br />Namaste -- do stop back.<br /><br />Condorhttp://shearlingsplowed.blogspot.comnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-59799791812260034042016-10-26T18:55:43.488-04:002016-10-26T18:55:43.488-04:00Agree with Anon - this is a bigger deal than not a...Agree with Anon - this is a bigger deal than not and post-ESMO the docs are starting to discuss that Opdivo and Keytruda are more non-alike than alike.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-11405534687749728212016-08-06T11:09:47.029-04:002016-08-06T11:09:47.029-04:00Well-put.
I do still think BMS will be fine with ...Well-put.<br /><br />I do still think BMS will be fine with Opdivo. But I agree about reaching for too much, from the science perspective -- a la Icarus -- flying too close to the Sun...<br /><br />NamasteCondorhttp://shearlingsplowed.bligspot.comnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-29991937755450957422016-08-06T11:05:55.067-04:002016-08-06T11:05:55.067-04:00I usually am in full agreement with you but not th...I usually am in full agreement with you but not this time. This is a big deal, bigger than you make us believe. Underlying this story is the fact that BMS consistently has de-emphasized the value of a biomarker(s), even an imperfect one like PD-L1, to guide patient selection, thereby ignoring the science that should drive decision making. In this case BMS paid a steep price. It looks like Merck on the other hand stuck with the science and the outcome apparently is very different.<br /><br />Although BMS will likely recover, it highlights what happens if one moves away from core principles - in this case scientific rigorAnonymousnoreply@blogger.com